Document is current

Article History

Received: 29 January 2021

Accepted: 7 April 2021

First Online: 23 April 2021

Declarations

:

: This study was reviewed and approved by appropriate institutional review boards and was conducted according to the Declaration of Helsinki. All participants gave written informed consent. The ethical review boards included Quorum Review, Inc., IRB Services, NRES Committee London – City and East, Egeszsegugyi Tudomanyos Tanacs, Bimetra -UZ Gent, CPP Tours - Région Centre (Ouest-1), Hospital Universitario La Fe de Valencia, Eticka komise IKEM a Thomayerova nemocnice, Landesamt für Gesundheit und Soziales (LAGeSo), Isala Klinieken METC, Tatsuoka Neurology Clinic, Dr. Mano Medical Clinic, Nihonbashi Sakura Clinic, Sugiura Clinic Institutional Review Board, Oita Central Institutional Review Board, Tominaga Hospital, Dokkyo Medical University Hospital, Tokyo-Eki Center-Building Clinic, NPO Clinical research promotion network Japan IRB, Severance Hospital Yonsei University Health System, Nowon Eulji Medical Center, Eulji University, Seoul National University Hospital, and Kangbuk Samsung Hosp.

: Not applicable.

: DKK, YD, and LYM are full-time employees of Eli Lilly and Company, and/or minor stockholders of the sponsor of the work, Eli Lilly and Company. JT has received compensation from Eli Lilly and Company for speaking and advisory board service, and indirect compensation for work related to clinical trials. SKA is an employee of Impel NeuroPharma. ALG has received compensation from Allergan Canada, Eli Lilly and Company, and Novartis.